FATE THERAPEUTICS INC Cash and Cash Equivalents, Period Increase (Decrease)
FATE THERAPEUTICS INC (FATE) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$48.00 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-15.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-05-15
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$48.00M.
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was $51.51M.
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was $1.23M.
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2016-06-30 was -$3.62M, a 109.32% decline year-over-year.
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was $23.80M, a 51.52% increase from fiscal 2015.
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was $15.71M.
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$4.93M, a 110.98% decline from fiscal 2013.
- FATE THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2013 was $44.95M, a 1564.78% increase from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 77 month | Cash and Cash Equivalents, Period Increase (Decrease) 80 month | Cash and Cash Equivalents, Period Increase (Decrease) 83 month |
|---|---|---|---|---|---|---|---|
| 2017-03-31 | -$48.00M 10-Q · filed 2017-05-15 | $3.51M derived: sum of 2 quarters · filed 2017-05-15 | $4.74M derived: sum of 3 quarters · filed 2017-05-15 | $1.12M derived: sum of 4 quarters · filed 2017-05-15 | |||
| 2016-12-31 | $51.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $52.74M derived: sum of 2 quarters · filed 2017-03-16 | $49.12M derived: sum of 3 quarters · filed 2017-03-16 | $23.80M 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$2.39M derived: sum of 2 quarters · filed 2016-11-07 | -$27.71M 10-Q · filed 2016-11-07 | -$35.76M derived: sum of 4 quarters · filed 2017-05-15 | |||
| 2016-06-30 | -$3.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$28.94M 10-Q · filed 2016-08-08 | -$36.99M derived: sum of 3 quarters · filed 2017-05-15 | -$45.31M derived: sum of 4 quarters · filed 2017-05-15 | |||
| 2016-03-31 | -$25.32M 10-Q · filed 2017-05-15 | -$33.37M derived: sum of 2 quarters · filed 2017-05-15 | -$41.69M derived: sum of 3 quarters · filed 2017-05-15 | -$2.86M derived: sum of 4 quarters · filed 2017-05-15 | |||
| 2015-12-31 | -$8.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$16.37M derived: sum of 2 quarters · filed 2017-03-16 | $22.46M derived: sum of 3 quarters · filed 2017-03-16 | $15.71M 10-K · filed 2017-03-16 | |||
| 2015-09-30 | -$8.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $30.51M derived: sum of 2 quarters · filed 2016-11-07 | $23.76M 10-Q · filed 2016-11-07 | $27.33M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $38.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $32.08M 10-Q · filed 2016-08-08 | $35.65M derived: sum of 3 quarters · filed 2017-03-16 | $39.16M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | -$6.75M 10-Q · filed 2016-05-09 | -$3.18M derived: sum of 2 quarters · filed 2017-03-16 | $337.00K derived: sum of 3 quarters · filed 2017-03-16 | -$5.53M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $7.09M derived: sum of 2 quarters · filed 2017-03-16 | $1.22M derived: sum of 3 quarters · filed 2017-03-16 | -$4.93M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | -$2.35M derived: sum of 2 quarters · filed 2015-11-03 | -$8.51M 10-Q · filed 2015-11-03 | $26.45M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | -$5.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$12.02M 10-Q · filed 2015-08-05 | $22.93M derived: sum of 3 quarters · filed 2016-03-03 | $38.61M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | -$6.16M 10-Q · filed 2015-05-07 | $28.80M derived: sum of 2 quarters · filed 2016-03-03 | $44.48M derived: sum of 3 quarters · filed 2016-03-03 | $43.23M derived: sum of 4 quarters · filed 2016-03-03 | $47.88M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $34.95M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $50.64M derived: sum of 2 quarters · filed 2016-03-03 | $49.39M derived: sum of 3 quarters · filed 2016-03-03 | $44.95M 10-K · filed 2016-03-03 | $54.04M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $15.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $14.44M derived: sum of 2 quarters · filed 2014-11-12 | $9.99M 10-Q · filed 2014-11-12 | $13.62M derived: sum of 4 quarters · filed 2015-03-12 | $19.08M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | -$5.69M 10-Q · filed 2014-08-12 | -$2.06M derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$4.44M 10-Q · filed 2014-05-13 | -$817.00K derived: sum of 2 quarters · filed 2015-03-12 | |||||
| 2012-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $2.70M 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | -$923.00K 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | -$4.84M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |